Literature DB >> 12029550

Sensitivity of 123I whole-body scan and thyroglobulin in the detection of metastases or recurrent differentiated thyroid cancer.

Lioe-Fee de Geus-Oei1, Hong-Yoe Oei, Georg Hennemann, Eric P Krenning.   

Abstract

Primary treatment of differentiated thyroid carcinoma consists of total thyroidectomy followed by ablation of thyroid tissue remnants and possible metastases by means of radioactive iodine. After complete destruction of remnants, metastases or recurrence can be detected by measurement of the serum thyroglobulin level as well as by radionuclide methods. Here we report on the sensitivity of diagnostic 123I scintigraphy and serum thyroglobulin measurement for tumour detection in patients with proven recurrence or metastases. Fifty-five patients who received their first high activity (1,850-5,550 MBq) of 123I therapy after total thyroidectomy and 131I ablation were included in the study. The thyroglobulin level was measured both during TSH-suppressive L-thyroxine therapy (Tg-on) and 4-6 weeks after L-thyroxine withdrawal (Tg-off, TSH>20 mU/l). Prior to treatment, whole-body scanning (WBS) was performed 24 h after the administration of 111-370 MBq 123I. The therapeutic activity of 1,850-5,550 MBq 131I was administered within 24 h after diagnostic scanning. The mean interval between 131I therapy and post-therapeutic WBS was 8.6 days (range 3-15 days). The sensitivity of WBS, Tg-on and Tg-off was 75%, 82% and 98%, respectively. The overall sensitivity of the combination of Tg-on with WBS and of Tg-off with WBS was 95% and 100%, respectively. In 12 out of 51 cases either Tg-off or Tg-on or both Tg-on and Tg-off levels were elevated while 123I-WBS was negative. More lesions were visible on the post-therapeutic 131I scan than on the corresponding diagnostic 123I scan (n=13). Tg values increased significantly (P<0.0001) after thyroid hormone withdrawal. Early treatment of distant metastases or tumour remnants of differentiated thyroid carcinoma is favoured and 131I treatment should also be considered in patients with a negative WBS but positive serum Tg level. The finding of a positive Tg-off level, which is clearly above the corresponding Tg-on value, is sufficient to make this decision. Additional diagnostic 123I WBS will not improve sensitivity.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12029550     DOI: 10.1007/s00259-002-0781-x

Source DB:  PubMed          Journal:  Eur J Nucl Med Mol Imaging        ISSN: 1619-7070            Impact factor:   9.236


  6 in total

Review 1.  Somatostatin receptor SPECT.

Authors:  Giovanna Pepe; Roy Moncayo; Emilio Bombardieri; Arturo Chiti
Journal:  Eur J Nucl Med Mol Imaging       Date:  2012-02       Impact factor: 9.236

2.  Surgery and survival outcomes of 22 patients with epidural spinal cord compression caused by thyroid tumor spinal metastases.

Authors:  Dan Zhang; Huabin Yin; Zhipeng Wu; Xinghai Yang; Tielong Liu; Jianru Xiao
Journal:  Eur Spine J       Date:  2012-10-18       Impact factor: 3.134

3.  Comparison of radioiodine biokinetics following the administration of recombinant human thyroid stimulating hormone and after thyroid hormone withdrawal in thyroid carcinoma.

Authors:  Markus Luster; Steven I Sherman; Monica C Skarulis; James R Reynolds; Michael Lassmann; Heribert Hänscheid; Christoph Reiners
Journal:  Eur J Nucl Med Mol Imaging       Date:  2003-07-15       Impact factor: 9.236

Review 4.  Bone metastases in thyroid cancer.

Authors:  Nicole M Iñiguez-Ariza; Keith C Bible; Bart L Clarke
Journal:  J Bone Oncol       Date:  2020-02-19       Impact factor: 4.072

5.  Clinical features of bone metastasis for differentiated thyroid carcinoma: A study of 21 patients from a Tunisian center.

Authors:  Faouzi Kallel; Fatma Hamza; Salma Charfeddine; Wissem Amouri; Issam Jardak; Abdelmonem Ghorbel; Fadhel Guermazi
Journal:  Indian J Endocrinol Metab       Date:  2014-03

6.  Radioiodine in Differentiated Thyroid Carcinoma: Do We Need Diagnostic Pre-Ablation Iodine-123 Scintigraphy to Optimize Treatment?

Authors:  Elizabeth J de Koster; Taban Sulaiman; Jaap F Hamming; Abbey Schepers; Marieke Snel; Floris H P van Velden; Lioe-Fee de Geus-Oei; Dennis Vriens
Journal:  Diagnostics (Basel)       Date:  2021-03-19
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.